USPTO serial 99464336
AADI BIOSCIENCE
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Oct 13, 2026
- Examiner
- HWANG, JOHN C B
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with AADI BIOSCIENCE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Morristown, NJ, US
Morristown, NJ, US
Morristown, NJ, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Aaron D. Hendelman
Aaron D. Hendelman WILSON SONSINI GOODRICH & ROSATI650 Page Mill RoadPalo Alto, CA 94304United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for the treatment and prevention of cancer, cardiovascular disease, epilepsy and mitochondrial disease; Vaccine preparations; Pharmaceutical preparations, namely, a drug formulation comprising nanoparticles of sirolimus and albumin for use in the treatment of diseases and disorders in the fields of angiology, cardiology, endocrinology, gastroenterology, geriatrics, hematology, hepatology, nephrology, neurology, oncology, pulmonology, pneumology, respirology, rheumatology, anesthesiology, urology, dermatology, gynecology, ophthalmology, infectiology, and psychiatry; Pharmaceutical preparations, namely, a drug formulation comprising nanoparticles of sirolimus and albumin for use in pediatric, geriatric, emergency, family, and human preventative medicine for the treatment of cancer, cardiovascular disease, epilepsy and mitochondrial disease; Pharmaceutical preparations for the treatment of cancer, cardiovascular disease, epilepsy and mitochondrial disease; Pharmaceutical preparations for the treatment of vascular malformations; Pharmaceutical preparations for the prevention and treatment of vascular system related diseases and disorders; Pharmaceutical preparations for use in plastic surgery; Pharmaceutical preparations for the treatment of tissue overgrowth related diseases and disorders; Pharmaceutical preparations for the treatment of vascular anomalies; all of the foregoing excluding pharmaceutical preparations for the treatment of sexual dysfunction and sexual disorders | ACTIVE | Feb 21, 2022 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 13, 2026 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Oct 13, 2026 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Sep 23, 2026 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| Sep 23, 2026 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| Sep 22, 2026 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Sep 2, 2026 | IUAF | USE AMENDMENT FILED | — |
| Sep 2, 2026 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Jul 2, 2026 | CHPB | POST PUBLICATION AMENDMENT - ENTERED | — |
| Jun 25, 2026 | APET | ASSIGNED TO PETITION STAFF | — |
| Jun 2, 2026 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| May 6, 2026 | EPPA | TEAS POST PUBLICATION AMENDMENT RECEIVED | — |
| Apr 7, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 7, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 1, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 12, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Mar 12, 2026 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Mar 12, 2026 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Mar 12, 2026 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Mar 12, 2026 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Mar 12, 2026 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Mar 12, 2026 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Mar 12, 2026 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Mar 12, 2026 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Mar 11, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 8, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 7, 2026 | MDSC | NOTICE OF DESIGN SEARCH CODE E-MAILED | — |
| Oct 27, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Oct 27, 2025 | NWAP | NEW APPLICATION ENTERED | — |